<DOC>
	<DOCNO>NCT00488800</DOCNO>
	<brief_summary>This postmarketing surveillance study evaluate safety profile Prevenar Indian child . Prevenar indicate active immunization infant child 6 week age 9 year age invasive disease ( include meningitis , bacteraemic pneumonia , bacteraemia , sepsis ) cause Streptococcus pneumoniae serotypes 4 , 6B , 9V , 14 , 18C , 19F 23F . Prevenar market India since June 2006 . The Board Health India give restrict permission import market Prevenar . The present study post-approval regulatory commitment Board Health India . This observational study protocol study approve Board Health .</brief_summary>
	<brief_title>Safety Local Tolerability Prevenar Indian Children</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>INCLUSION CRITERIA Subjects must meet least one follow condition eligible inclusion study : For Primary Immunization Schedule : Healthy male female subject 6 week + 5 day age previous PREVENAR vaccination For Catchup Immunization Schedule : Healthy male female subject 1223 month age EXCLUSION CRITERIA Subjects follow condition characteristic exclude study . A known suspected history Streptococcus pneumoniae disease . A previous anaphylactic severe vaccineassociated adverse event . A know suspected impairment immune system ( include HIV infection ) , recipient immunosuppressive agent . A major congenital , developmental serious chronic disorder . A confirmed suspected underlie evolve neurological disorder history seizure . A history thrombocytopenia coagulation disorder . Any acute illness time vaccine administration</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Pneumococcal Infections/PC ( Prevention &amp; Control )</keyword>
</DOC>